Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 12 March, 2025
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo
Stock Ticker - BSE: 543332 | NSE: EPIGRAL

Epigral Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: March 11, 2025, 10:46 pm

Market Cap 7,799 Cr.
Current Price 1,808
High / Low 2,408/940
Stock P/E22.5
Book Value 324
Dividend Yield0.28 %
ROCE17.5 %
ROE16.9 %
Face Value 10.0
PEG Ratio0.82

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Epigral Ltd

Competitors of Epigral Ltd

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Epigral Ltd 7,799 Cr. 1,808 2,408/94022.5 3240.28 %17.5 %16.9 % 10.0
Dharmaj Crop Guard Ltd 663 Cr. 197 390/16519.6 1170.00 %14.5 %13.2 % 10.0
Bhaskar Agrochemicals Ltd 39.6 Cr. 76.0 122/46.117.5 29.20.00 %14.7 %13.4 % 10.0
Bhagiradha Chemicals & Industries Ltd 3,872 Cr. 297 448/151128 51.00.03 %8.71 %5.55 % 1.00
Best Agrolife Ltd 695 Cr. 296 756/24636.0 3201.01 %16.5 %18.1 % 10.0
Industry Average10,095.70 Cr1,496.0535.79421.930.41%13.25%14.87%7.25

All Competitor Stocks of Epigral Ltd

Quarterly Result

MetricDec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Sales 422499533556538562455478472525651626645
Expenses 281324345375371407360370349369475448463
Operating Profit 14117518718016715595108123155176178183
OPM % 33%35%35%32%31%28%21%23%26%30%27%28%28%
Other Income -0222-052122264
Interest 101211142119182120141427-0
Depreciation 22212226313031323130333233
Profit before tax 109144156142114110485674113131124154
Tax % 36%31%31%35%33%30%33%32%34%32%34%35%33%
Net Profit 7099108927777323849778681104
EPS in Rs 16.7823.8525.9422.0418.5818.487.629.1811.8718.4520.7019.3824.00

Last Updated: March 4, 2025, 12:24 pm

Below is a detailed analysis of the quarterly data for Epigral Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

  • For Sales, as of Dec 2024, the value is ₹645.00 Cr.. The value appears strong and on an upward trend. It has increased from 626.00 Cr. (Sep 2024) to ₹645.00 Cr., marking an increase of ₹19.00 Cr..
  • For Expenses, as of Dec 2024, the value is ₹463.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 448.00 Cr. (Sep 2024) to ₹463.00 Cr., marking an increase of ₹15.00 Cr..
  • For Operating Profit, as of Dec 2024, the value is ₹183.00 Cr.. The value appears strong and on an upward trend. It has increased from 178.00 Cr. (Sep 2024) to ₹183.00 Cr., marking an increase of ₹5.00 Cr..
  • For OPM %, as of Dec 2024, the value is 28.00%. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 28.00%.
  • For Other Income, as of Dec 2024, the value is ₹4.00 Cr.. The value appears to be declining and may need further review. It has decreased from 6.00 Cr. (Sep 2024) to ₹4.00 Cr., marking a decrease of 2.00 Cr..
  • For Interest, as of Dec 2024, the value is ₹0.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 27.00 Cr. (Sep 2024) to ₹0.00 Cr., marking a decrease of 27.00 Cr..
  • For Depreciation, as of Dec 2024, the value is ₹33.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 32.00 Cr. (Sep 2024) to ₹33.00 Cr., marking an increase of ₹1.00 Cr..
  • For Profit before tax, as of Dec 2024, the value is ₹154.00 Cr.. The value appears strong and on an upward trend. It has increased from 124.00 Cr. (Sep 2024) to ₹154.00 Cr., marking an increase of ₹30.00 Cr..
  • For Tax %, as of Dec 2024, the value is 33.00%. The value appears to be improving (decreasing) as expected. It has decreased from 35.00% (Sep 2024) to 33.00%, marking a decrease of 2.00%.
  • For Net Profit, as of Dec 2024, the value is ₹104.00 Cr.. The value appears strong and on an upward trend. It has increased from 81.00 Cr. (Sep 2024) to ₹104.00 Cr., marking an increase of ₹23.00 Cr..
  • For EPS in Rs, as of Dec 2024, the value is 24.00. The value appears strong and on an upward trend. It has increased from ₹19.38 (Sep 2024) to 24.00, marking an increase of ₹4.62.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 1:12 pm

MetricMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024TTM
Sales 3943925987106118291,5512,1881,9292,447
Expenses 2452483464054165671,0411,4991,4481,754
Operating Profit 149144252306194261510689481693
OPM % 38%37%42%43%32%32%33%31%25%28%
Other Income 218162248613
Interest 1914925112944667355
Depreciation 44555554447486109124129
Profit before tax 8875195242141161383523291522
Tax % 23%11%20%25%21%37%34%32%33%
Net Profit 6767155183112101253353196347
EPS in Rs 9.499.4021.9744.3827.1924.4860.8485.0447.1282.53
Dividend Payout % 0%0%0%0%0%0%0%6%11%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)0.00%131.34%18.06%-38.80%-9.82%150.50%39.53%-44.48%
Change in YoY Net Profit Growth (%)0.00%131.34%-113.28%-56.86%28.98%160.32%-110.97%-84.00%

Epigral Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 8 years from 2016-2017 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:%
5 Years:22%
3 Years:33%
TTM:24%
Compounded Profit Growth
10 Years:%
5 Years:2%
3 Years:25%
TTM:77%
Stock Price CAGR
10 Years:%
5 Years:%
3 Years:27%
1 Year:76%
Return on Equity
10 Years:%
5 Years:30%
3 Years:30%
Last Year:17%

Last Updated: Unknown

Balance Sheet

Last Updated: November 14, 2024, 4:32 pm

MonthMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital 71717141424242424242
Reserves 2242914472413314326841,0281,2131,358
Borrowings 19012374601737753993879964904
Other Liabilities 554279162164223405484576676
Total Liabilities 5405276711,0441,2731,4492,1242,4322,7942,979
Fixed Assets 3643983472954401,1021,0681,8041,7671,912
CWIP 69379468691126589158483350
Investments 029710000212121
Other Assets 10698173281142221467449524696
Total Assets 5405276711,0441,2731,4492,1242,4322,7942,979

Below is a detailed analysis of the balance sheet data for Epigral Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2024, the value is ₹42.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹42.00 Cr..
  • For Reserves, as of Sep 2024, the value is ₹1,358.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹1,213.00 Cr. (Mar 2024) to ₹1,358.00 Cr., marking an increase of 145.00 Cr..
  • For Borrowings, as of Sep 2024, the value is ₹904.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from ₹964.00 Cr. (Mar 2024) to ₹904.00 Cr., marking a decrease of 60.00 Cr..
  • For Other Liabilities, as of Sep 2024, the value is ₹676.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹576.00 Cr. (Mar 2024) to ₹676.00 Cr., marking an increase of 100.00 Cr..
  • For Total Liabilities, as of Sep 2024, the value is ₹2,979.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹2,794.00 Cr. (Mar 2024) to ₹2,979.00 Cr., marking an increase of 185.00 Cr..
  • For Fixed Assets, as of Sep 2024, the value is ₹1,912.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹1,767.00 Cr. (Mar 2024) to ₹1,912.00 Cr., marking an increase of 145.00 Cr..
  • For CWIP, as of Sep 2024, the value is ₹350.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹483.00 Cr. (Mar 2024) to ₹350.00 Cr., marking a decrease of 133.00 Cr..
  • For Investments, as of Sep 2024, the value is ₹21.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹21.00 Cr..
  • For Other Assets, as of Sep 2024, the value is ₹696.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹524.00 Cr. (Mar 2024) to ₹696.00 Cr., marking an increase of 172.00 Cr..
  • For Total Assets, as of Sep 2024, the value is ₹2,979.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹2,794.00 Cr. (Mar 2024) to ₹2,979.00 Cr., marking an increase of 185.00 Cr..

Notably, the Reserves (₹1,358.00 Cr.) exceed the Borrowings (904.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +165229284626398
Cash from Investing Activity +-363-197-455-437-401
Cash from Financing Activity +69-32195-200-8
Net Cash Flow-129124-11-11

Free Cash Flow

MonthMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow-41.0021.00178.00-295.00-543.00-492.00-483.00-190.00-483.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days434147404652602834
Inventory Days755945586451746990
Days Payable313751526269423657
Cash Conversion Cycle866342464834926167
Working Capital Days434019-26-65-59261525
ROCE %18%37%36%15%16%29%32%17%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Promoters71.18%71.11%71.12%71.21%71.34%71.37%71.38%71.38%71.49%71.58%71.58%68.94%
FIIs1.02%1.38%1.40%1.15%1.20%1.16%1.14%1.17%1.36%1.46%2.10%3.01%
DIIs0.47%0.22%0.19%0.17%0.03%0.04%0.04%0.05%0.02%0.18%1.17%4.31%
Government0.02%0.02%0.02%0.02%0.02%0.02%0.02%0.02%0.02%0.02%0.02%0.02%
Public27.31%27.27%27.26%27.44%27.39%27.39%27.40%27.37%27.10%26.75%25.12%23.71%
No. of Shareholders92,18593,14797,39697,01694,77895,83395,74292,95988,87085,76183,17681,697

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.00
Basic EPS (Rs.) 47.1485.0360.8424.27
Diluted EPS (Rs.) 47.1485.0360.8424.27
Cash EPS (Rs.) 76.87111.2581.5141.97
Book Value[Excl.RevalReserv]/Share (Rs.) 301.83257.30174.72113.88
Book Value[Incl.RevalReserv]/Share (Rs.) 301.83257.30174.72113.88
Revenue From Operations / Share (Rs.) 464.30526.69373.27199.41
PBDIT / Share (Rs.) 117.39167.73123.6163.42
PBIT / Share (Rs.) 87.66141.51102.9345.72
PBT / Share (Rs.) 69.97125.7592.2838.71
Net Profit / Share (Rs.) 47.1385.0360.8424.27
NP After MI And SOA / Share (Rs.) 47.1485.0360.8424.27
PBDIT Margin (%) 25.2831.8433.1131.80
PBIT Margin (%) 18.8726.8627.5722.92
PBT Margin (%) 15.0623.8724.7219.41
Net Profit Margin (%) 10.1516.1416.2912.16
NP After MI And SOA Margin (%) 10.1516.1416.2912.16
Return on Networth / Equity (%) 15.6133.0434.8221.30
Return on Capital Employeed (%) 18.0732.9426.8717.92
Return On Assets (%) 7.0014.5211.906.96
Long Term Debt / Equity (X) 0.390.401.060.71
Total Debt / Equity (X) 0.720.711.360.87
Asset Turnover Ratio (%) 0.730.960.860.00
Current Ratio (X) 0.640.640.830.46
Quick Ratio (X) 0.300.320.550.32
Inventory Turnover Ratio (X) 4.516.627.300.00
Dividend Payout Ratio (NP) (%) 5.302.940.000.00
Dividend Payout Ratio (CP) (%) 3.252.240.000.00
Earning Retention Ratio (%) 94.7097.060.000.00
Cash Earning Retention Ratio (%) 96.7597.760.000.00
Interest Coverage Ratio (X) 6.6410.6411.609.05
Interest Coverage Ratio (Post Tax) (X) 3.666.396.714.46
Enterprise Value (Cr.) 5509.594780.475010.230.00
EV / Net Operating Revenue (X) 2.862.183.230.00
EV / EBITDA (X) 11.306.869.760.00
MarketCap / Net Operating Revenue (X) 2.361.792.610.00
Retention Ratios (%) 94.6997.050.000.00
Price / BV (X) 3.633.675.570.00
Price / Net Operating Revenue (X) 2.361.792.610.00
EarningsYield 0.040.090.060.00

After reviewing the key financial ratios for Epigral Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
  • For Basic EPS (Rs.), as of Mar 24, the value is 47.14. This value is within the healthy range. It has decreased from 85.03 (Mar 23) to 47.14, marking a decrease of 37.89.
  • For Diluted EPS (Rs.), as of Mar 24, the value is 47.14. This value is within the healthy range. It has decreased from 85.03 (Mar 23) to 47.14, marking a decrease of 37.89.
  • For Cash EPS (Rs.), as of Mar 24, the value is 76.87. This value is within the healthy range. It has decreased from 111.25 (Mar 23) to 76.87, marking a decrease of 34.38.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 301.83. It has increased from 257.30 (Mar 23) to 301.83, marking an increase of 44.53.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 301.83. It has increased from 257.30 (Mar 23) to 301.83, marking an increase of 44.53.
  • For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 464.30. It has decreased from 526.69 (Mar 23) to 464.30, marking a decrease of 62.39.
  • For PBDIT / Share (Rs.), as of Mar 24, the value is 117.39. This value is within the healthy range. It has decreased from 167.73 (Mar 23) to 117.39, marking a decrease of 50.34.
  • For PBIT / Share (Rs.), as of Mar 24, the value is 87.66. This value is within the healthy range. It has decreased from 141.51 (Mar 23) to 87.66, marking a decrease of 53.85.
  • For PBT / Share (Rs.), as of Mar 24, the value is 69.97. This value is within the healthy range. It has decreased from 125.75 (Mar 23) to 69.97, marking a decrease of 55.78.
  • For Net Profit / Share (Rs.), as of Mar 24, the value is 47.13. This value is within the healthy range. It has decreased from 85.03 (Mar 23) to 47.13, marking a decrease of 37.90.
  • For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 47.14. This value is within the healthy range. It has decreased from 85.03 (Mar 23) to 47.14, marking a decrease of 37.89.
  • For PBDIT Margin (%), as of Mar 24, the value is 25.28. This value is within the healthy range. It has decreased from 31.84 (Mar 23) to 25.28, marking a decrease of 6.56.
  • For PBIT Margin (%), as of Mar 24, the value is 18.87. This value is within the healthy range. It has decreased from 26.86 (Mar 23) to 18.87, marking a decrease of 7.99.
  • For PBT Margin (%), as of Mar 24, the value is 15.06. This value is within the healthy range. It has decreased from 23.87 (Mar 23) to 15.06, marking a decrease of 8.81.
  • For Net Profit Margin (%), as of Mar 24, the value is 10.15. This value exceeds the healthy maximum of 10. It has decreased from 16.14 (Mar 23) to 10.15, marking a decrease of 5.99.
  • For NP After MI And SOA Margin (%), as of Mar 24, the value is 10.15. This value is within the healthy range. It has decreased from 16.14 (Mar 23) to 10.15, marking a decrease of 5.99.
  • For Return on Networth / Equity (%), as of Mar 24, the value is 15.61. This value is within the healthy range. It has decreased from 33.04 (Mar 23) to 15.61, marking a decrease of 17.43.
  • For Return on Capital Employeed (%), as of Mar 24, the value is 18.07. This value is within the healthy range. It has decreased from 32.94 (Mar 23) to 18.07, marking a decrease of 14.87.
  • For Return On Assets (%), as of Mar 24, the value is 7.00. This value is within the healthy range. It has decreased from 14.52 (Mar 23) to 7.00, marking a decrease of 7.52.
  • For Long Term Debt / Equity (X), as of Mar 24, the value is 0.39. This value is within the healthy range. It has decreased from 0.40 (Mar 23) to 0.39, marking a decrease of 0.01.
  • For Total Debt / Equity (X), as of Mar 24, the value is 0.72. This value is within the healthy range. It has increased from 0.71 (Mar 23) to 0.72, marking an increase of 0.01.
  • For Asset Turnover Ratio (%), as of Mar 24, the value is 0.73. It has decreased from 0.96 (Mar 23) to 0.73, marking a decrease of 0.23.
  • For Current Ratio (X), as of Mar 24, the value is 0.64. This value is below the healthy minimum of 1.5. There is no change compared to the previous period (Mar 23) which recorded 0.64.
  • For Quick Ratio (X), as of Mar 24, the value is 0.30. This value is below the healthy minimum of 1. It has decreased from 0.32 (Mar 23) to 0.30, marking a decrease of 0.02.
  • For Inventory Turnover Ratio (X), as of Mar 24, the value is 4.51. This value is within the healthy range. It has decreased from 6.62 (Mar 23) to 4.51, marking a decrease of 2.11.
  • For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 5.30. This value is below the healthy minimum of 20. It has increased from 2.94 (Mar 23) to 5.30, marking an increase of 2.36.
  • For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 3.25. This value is below the healthy minimum of 20. It has increased from 2.24 (Mar 23) to 3.25, marking an increase of 1.01.
  • For Earning Retention Ratio (%), as of Mar 24, the value is 94.70. This value exceeds the healthy maximum of 70. It has decreased from 97.06 (Mar 23) to 94.70, marking a decrease of 2.36.
  • For Cash Earning Retention Ratio (%), as of Mar 24, the value is 96.75. This value exceeds the healthy maximum of 70. It has decreased from 97.76 (Mar 23) to 96.75, marking a decrease of 1.01.
  • For Interest Coverage Ratio (X), as of Mar 24, the value is 6.64. This value is within the healthy range. It has decreased from 10.64 (Mar 23) to 6.64, marking a decrease of 4.00.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 3.66. This value is within the healthy range. It has decreased from 6.39 (Mar 23) to 3.66, marking a decrease of 2.73.
  • For Enterprise Value (Cr.), as of Mar 24, the value is 5,509.59. It has increased from 4,780.47 (Mar 23) to 5,509.59, marking an increase of 729.12.
  • For EV / Net Operating Revenue (X), as of Mar 24, the value is 2.86. This value is within the healthy range. It has increased from 2.18 (Mar 23) to 2.86, marking an increase of 0.68.
  • For EV / EBITDA (X), as of Mar 24, the value is 11.30. This value is within the healthy range. It has increased from 6.86 (Mar 23) to 11.30, marking an increase of 4.44.
  • For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 2.36. This value is within the healthy range. It has increased from 1.79 (Mar 23) to 2.36, marking an increase of 0.57.
  • For Retention Ratios (%), as of Mar 24, the value is 94.69. This value exceeds the healthy maximum of 70. It has decreased from 97.05 (Mar 23) to 94.69, marking a decrease of 2.36.
  • For Price / BV (X), as of Mar 24, the value is 3.63. This value exceeds the healthy maximum of 3. It has decreased from 3.67 (Mar 23) to 3.63, marking a decrease of 0.04.
  • For Price / Net Operating Revenue (X), as of Mar 24, the value is 2.36. This value is within the healthy range. It has increased from 1.79 (Mar 23) to 2.36, marking an increase of 0.57.
  • For EarningsYield, as of Mar 24, the value is 0.04. This value is below the healthy minimum of 5. It has decreased from 0.09 (Mar 23) to 0.04, marking a decrease of 0.05.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Epigral Ltd as of March 12, 2025 is: ₹988.37

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 12, 2025, Epigral Ltd is Overvalued by 45.33% compared to the current share price 1,808.00

Intrinsic Value of Epigral Ltd as of March 12, 2025 is: 1,260.32

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 12, 2025, Epigral Ltd is Overvalued by 30.29% compared to the current share price 1,808.00

Last 5 Year EPS CAGR: 27.51%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 22.22%, which is a positive sign.
  2. The stock has a low average Working Capital Days of 2.00, which is a positive sign.
  3. The company has higher reserves (624.90 cr) compared to borrowings (621.80 cr), indicating strong financial stability.
  4. The company has shown consistent growth in sales (354.00 cr) and profit (262.10 cr) over the years.
  1. The stock has a high average Cash Conversion Cycle of 59.89, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Epigral Ltd:
    1. Net Profit Margin: 10.15%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 18.07% (Industry Average ROCE: 13.25%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 15.61% (Industry Average ROE: 14.87%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 3.66
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 0.3
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 22.5 (Industry average Stock P/E: 35.79)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.72
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Epigral Ltd. is a Public Limited Listed company incorporated on 11/09/2007 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24100GJ2007PLC051717 and registration number is 051717. Currently Company is involved in the business activities of Manufacture of organic and inorganic chemical compounds. Company's Total Operating Revenue is Rs. 1929.19 Cr. and Equity Capital is Rs. 41.55 Cr. for the Year ended 31/03/2024.
INDUSTRYADDRESSCONTACT
Agro Chemicals/Pesticides�Epigral Tower�, Behind Safal Profitaire, Ahmedabad Gujarat 380015helpdesk@epigral.com
http://www.epigral.com
Management
NamePosition Held
Mr. Maulik Jayantibhai PatelChairman & Managing Director
Mr. Kaushal Ashish SoparkarExecutive Director
Mr. Ankit Natwarlal PatelNon Exe.Non Ind.Director
Mr. Karana Rameshbhai PatelNon Exe.Non Ind.Director
Mr. Darshan Anandbhai PatelNon Exe.Non Ind.Director
Mr. Manubhai PatelIndependent Director
Mr. Sanjay AsherIndependent Director
Mr. Kanubhai Shakarabhai PatelIndependent Director
Mr. Raju SwamyIndependent Director
Ms. Nirali ParikhIndependent Director

FAQ

What is the latest intrinsic value of Epigral Ltd?

The latest intrinsic value of Epigral Ltd as on 11 March 2025 is ₹988.37, which is 45.33% lower than the current market price of 1,808.00, indicating the stock is overvalued by 45.33%. The intrinsic value of Epigral Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹7,799 Cr. and recorded a high/low of ₹2,408/940 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹1,358 Cr and total liabilities of ₹2,979 Cr.

What is the Market Cap of Epigral Ltd?

The Market Cap of Epigral Ltd is 7,799 Cr..

What is the current Stock Price of Epigral Ltd as on 11 March 2025?

The current stock price of Epigral Ltd as on 11 March 2025 is ₹1,808.

What is the High / Low of Epigral Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Epigral Ltd stocks is ₹2,408/940.

What is the Stock P/E of Epigral Ltd?

The Stock P/E of Epigral Ltd is 22.5.

What is the Book Value of Epigral Ltd?

The Book Value of Epigral Ltd is 324.

What is the Dividend Yield of Epigral Ltd?

The Dividend Yield of Epigral Ltd is 0.28 %.

What is the ROCE of Epigral Ltd?

The ROCE of Epigral Ltd is 17.5 %.

What is the ROE of Epigral Ltd?

The ROE of Epigral Ltd is 16.9 %.

What is the Face Value of Epigral Ltd?

The Face Value of Epigral Ltd is 10.0.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Epigral Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE